Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
Immune checkpoint inhibitors (ICIs) therapy has revolutionized cancer treatment. However, it is important to acknowledge that ICI therapy can lead to immune-related adverse events (irAEs), including myocarditis. While early-onset myocarditis is well-documented, late-onset cases are increasingly reco...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/2/302 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231018913529856 |
|---|---|
| author | Harun Muğlu Erdem Sünger Bahadır Köylü Didem Tunalı Cengiz Erol Fatih Selcukbiricik Ahmet Bilici Omer Fatih Olmez |
| author_facet | Harun Muğlu Erdem Sünger Bahadır Köylü Didem Tunalı Cengiz Erol Fatih Selcukbiricik Ahmet Bilici Omer Fatih Olmez |
| author_sort | Harun Muğlu |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) therapy has revolutionized cancer treatment. However, it is important to acknowledge that ICI therapy can lead to immune-related adverse events (irAEs), including myocarditis. While early-onset myocarditis is well-documented, late-onset cases are increasingly recognized. This case series presents four cases of late-onset ICI-associated myocarditis, emphasizing the need for long-term surveillance of this potentially fatal complication. Patients exhibited a range of cardiac symptoms, including chest pain, shortness of breath, and arrhythmias. The diagnosis was confirmed through cardiac magnetic resonance imaging (MRI) and elevated cardiac biomarkers. Treatment involved the immediate discontinuation of ICI therapy and the initiation of high-dose corticosteroids. In cases with an inadequate response, additional immunosuppressive agents were considered. This case series underscores the importance of prolonged monitoring for late-onset ICI-associated myocarditis. Further research is needed to establish optimal treatment strategies and long-term management approaches for this complex condition. |
| format | Article |
| id | doaj-art-507fcbc6961d4a5e96589443358d85df |
| institution | OA Journals |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-507fcbc6961d4a5e96589443358d85df2025-08-20T02:03:40ZengMDPI AGMedicina1010-660X1648-91442025-02-0161230210.3390/medicina61020302Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature ReviewHarun Muğlu0Erdem Sünger1Bahadır Köylü2Didem Tunalı3Cengiz Erol4Fatih Selcukbiricik5Ahmet Bilici6Omer Fatih Olmez7Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34214, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34214, TurkeyDepartment of Medical Oncology, Istanbul Koc University, Istanbul 34450, TurkeyDepartment of Medical Oncology, Istanbul Koc University, Istanbul 34450, TurkeyDepartment of Radiology, Faculty of Medicine, Medipol University, Istanbul 34214, TurkeyDepartment of Medical Oncology, Istanbul Koc University, Istanbul 34450, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34214, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34214, TurkeyImmune checkpoint inhibitors (ICIs) therapy has revolutionized cancer treatment. However, it is important to acknowledge that ICI therapy can lead to immune-related adverse events (irAEs), including myocarditis. While early-onset myocarditis is well-documented, late-onset cases are increasingly recognized. This case series presents four cases of late-onset ICI-associated myocarditis, emphasizing the need for long-term surveillance of this potentially fatal complication. Patients exhibited a range of cardiac symptoms, including chest pain, shortness of breath, and arrhythmias. The diagnosis was confirmed through cardiac magnetic resonance imaging (MRI) and elevated cardiac biomarkers. Treatment involved the immediate discontinuation of ICI therapy and the initiation of high-dose corticosteroids. In cases with an inadequate response, additional immunosuppressive agents were considered. This case series underscores the importance of prolonged monitoring for late-onset ICI-associated myocarditis. Further research is needed to establish optimal treatment strategies and long-term management approaches for this complex condition.https://www.mdpi.com/1648-9144/61/2/302immune checkpoint inhibitorsimmune-related adverse events (irAEs)late-onset myocarditiscardiotoxicity |
| spellingShingle | Harun Muğlu Erdem Sünger Bahadır Köylü Didem Tunalı Cengiz Erol Fatih Selcukbiricik Ahmet Bilici Omer Fatih Olmez Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review Medicina immune checkpoint inhibitors immune-related adverse events (irAEs) late-onset myocarditis cardiotoxicity |
| title | Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review |
| title_full | Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review |
| title_fullStr | Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review |
| title_full_unstemmed | Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review |
| title_short | Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review |
| title_sort | late onset myocarditis following immune checkpoint inhibitors therapy a case series with literature review |
| topic | immune checkpoint inhibitors immune-related adverse events (irAEs) late-onset myocarditis cardiotoxicity |
| url | https://www.mdpi.com/1648-9144/61/2/302 |
| work_keys_str_mv | AT harunmuglu lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT erdemsunger lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT bahadırkoylu lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT didemtunalı lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT cengizerol lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT fatihselcukbiricik lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT ahmetbilici lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview AT omerfatiholmez lateonsetmyocarditisfollowingimmunecheckpointinhibitorstherapyacaseserieswithliteraturereview |